The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > ORGANIZATION
ORGANIZATION
- Pharma, Wholesaler Leaders Hold 1st Meeting with PM Kishida
November 30, 2021
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
- JPMA Director Gets Sarcastic on MOF’s Data Presentation on Drug Costs
November 19, 2021
- Sales Reps in Japan Log Record Decline in FY2020, Down for 7 Consecutive Years
November 17, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- JPWA Vows to Boost Compliance after New Bid-Rigging Probe
November 12, 2021
- Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
- Japan No. 3 Originator Country in Global Top 100 Drug List in 2020: JPMA Think Tank
November 11, 2021
- PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
- Kazuhiko Ezawa to Become Chuikyo JMA Rep after Matsumoto
October 28, 2021
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- IFPW Chair Vows to Boost Reliability of Healthcare Supply Chain as Tokyo Confab Ends
October 8, 2021
- INES’ Patient-Centered Policy Initiative Going Full Throttle, Proposal Eyed before 2022 Honebuto Paper
October 7, 2021
- JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…